ODAC To Assess Safety Of Lilly’s Evista As Breast Cancer Preventative
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is seeking advice from its Oncologic Drugs Advisory Committee on expectations for efficacy and risk when dealing with a drug to prevent breast cancer.